focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Creo device used in 'groundbreaking' lung cancer procedure

Fri, 01st Mar 2024 14:06

(Sharecast News) - Creo Medical Group announced a significant milestone in the field of minimally-invasive surgical endoscopy for cancer patients on Friday, with its 'MicroBlate Flex' device.

The AIM-traded company announced that professor Pallav Shah and Dr Christopher Orton, specialists from the Royal Brompton Hospital, had successfully conducted the world's first robotic-guided microwave ablation of lung tissue concurrently with a diagnostic procedure.

It said the pioneering procedure, using its MicroBlate Flex device, targeted a 27mm cancerous nodule within a patient's lung.

The achievement was considered a notable advancement in the medical community's ability to diagnose, stage, and treat lung cancer in a single sitting.

In a statement, Dr Orton emphasised the potential of the innovative approach, saying the "potential to combine the diagnosis, staging, and treatment of lung cancer in one procedure offers significant benefit to patients".

Creo said the procedure, conducted at the Royal Brompton Hospital in London, reportedly lasted just three minutes.

"Creo has been pioneering minimally invasive surgical endoscopy for pre-cancer and cancer patients for years, and implementing our technology into robotic application is a key goal for us as the adoption of this technology continues to grow exponentially," said chief executive officer Craig Gulliford.

"We are incredibly proud that our MicroBlate Flex technology has been able to make this world-first possible.

"The potential for these technologies to combine precise robotically guided lung cancer diagnosis with the ablation of cancerous tissue in one session is transformational."

Gulliford said that could "dramatically improve" outcomes for lung cancer patients, and had the potential to remove "long and worrying" delays between diagnosis and treatment.

"This is the beginning of an exciting programme and the team have done a terrific job in reaching this point."

At 1411 GMT, shares in Creo Medical Group were up 0.84% at 30p.

Reporting by Josh White for Sharecast.com.

Related Shares

More News
15 May 2024 12:11

Creo Medical on track to break even next year on strong 2023 results

(Alliance News) - Creo Medical Group PLC on Wednesday reported improved performance as the company expanded its product offerings.

8 May 2024 15:52

UK earnings, trading statements calendar - next 7 days

24 Apr 2024 16:04

TRADING UPDATES: ActiveOps sales up; Sancus turnover jumps

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday and not separately reported by Allian...

1 Mar 2024 13:34

EARNINGS AND TRADING: Dar Global celebrates "outstanding" year

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.